Gene therapy and pancreatic cancer. Front Biosci 1998 Nov 01;3:E230-7
Date
10/30/1998Pubmed ID
9792901DOI
10.2741/a382Scopus ID
2-s2.0-17944386032 (requires institutional sign-in at Scopus site) 25 CitationsAbstract
Adenocarcinoma of the pancreas is associated with a short survival due to frequent delays in diagnosis and the lack of effective systemic therapies. Advances in understanding the molecular basis of pancreatic cancer have allowed identification of molecular targets which are amenable to therapeutic intervention. Such targets include p53, K-ras, p16, and DPC-4. Gene therapy involves the transfer of genetic constructs which alter the neoplastic potential of the cancer cell. Vectors used in gene transfer include viral and non-viral methods. Presently, gene therapy of pancreatic cancer is limited to pre-clinical studies using in vitro and in vivo models. However, the initial results from these pre-clinical studies have been encouraging and will form the basis for clinical studies of gene transfer in patients with pancreatic cancer.
Author List
Pearson AS, Bouvet M, Evans DB, Roth JAAuthor
Douglas B. Evans MD Chair, Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdenocarcinomaCell Transformation, Neoplastic
Clinical Trials as Topic
DNA
DNA-Binding Proteins
Gene Expression Regulation, Neoplastic
Genes, bcl-2
Genes, p53
Genes, ras
Genetic Therapy
Genetic Vectors
Humans
Pancreatic Neoplasms
Smad4 Protein
Trans-Activators
